Developer docs
API playgroundTry for free, no card

Search company profiles

PermeaDerm

Full company profile

uuid000ymqp

Namestring
PermeaDerm
Legal namestring
PermeaDerm, Inc.
Websiteurl
permeaderm.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

PermeaDerm, Inc. is a San Diego-based medical device company that develops and commercializes a family of FDA 510(k)-cleared biosynthetic wound matrix products for the treatment of burns, chronic wounds, and surgical or traumatic wounds. The company's proprietary Biosynthetic Matrix (BSM) Technology combines a silicone membrane epidermal analogue (with variable slits for oxygen, carbon dioxide, and exudate diffusion) and a 3D micro-scaffold dermal analogue with bio-coating, configured with variable porosity to allow customization across wound types. The portfolio consists of three product variants: PermeaDerm-B for acute wounds (partial thickness burns, donor sites, surgical wounds), PermeaDerm-C for chronic wounds (diabetic ulcers, venous ulcers, pressure sores, vascular ulcers), and PermeaDerm-G (gloves) for debrided partial thickness hand burns. The technology operates through an R.A.S.E. mode of action — Reconstruction of skin barrier and ECM, primary Adherence within 5 hours, secondary Adherence (3D structure) within 72 hours, and Epithelialization.

PermeaDerm was founded by Dr. Aubrey Woodroof, the inventor of Biobrane (the first bilaminate biosynthetic temporary wound dressing) and holder of multiple patents covering Biobrane, AWOD, AWOD Plus, and PermeaDerm. The company received FDA 510(k) clearance in 2016 and ISO 13485 certification in 2018. In August 2019, PermeaDerm was acquired by Stedical Scientific (Shanghai) Co., Ltd., with Dr. Woodroof continuing as Chief Scientific Officer. Following the acquisition, Stedical Scientific provides the R&D and manufacturing infrastructure while leveraging top-tier distribution partners in the wound care, infection control, and burn markets for commercialization across the US, Europe, and Greater China. The company is also running multi-center clinical trials in the US and China (184 subjects across 4 Chinese centers) to support expanded regulatory approval and clinical evidence, with stated expansion intent into the Middle East, Southeast Asia, Africa, and Latin America.

The business model is primarily hardware sales of FDA-cleared medical devices through distribution partners, supplemented by clinical trial services in support of regulatory expansion. Pricing is not publicly disclosed. The company reports that thousands of patients have been treated in US burn centers since the 2020 US launch, with a cited clinical outcome of 9-day healing for deep second-degree burns versus a typical 3-7 week healing time. No revenue figures, headcount, or funding rounds are publicly disclosed.

Short descriptiontext

PermeaDerm develops FDA-cleared biosynthetic wound matrix products (PermeaDerm-B, -C, -G) for burn, chronic, and surgical wound care, leveraging variable porosity and R.A.S.E. healing technology, commercialized via distribution partners in the US, Europe, and Greater China.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCarlsbad, United States
HQ citystring
Carlsbad
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosynthetic wound matrix, burn care dressings, chronic wound care, skin substitute devices, medical device manufacturing
Industry6 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKACAN
Wound Care & Ulcer Management
SECONDARYHLAKAGAK
Wound Care & Diabetic Foot Infection
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAFAHAF
Burn Care Specialty Hospitals
Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Biosynthetic Wound Care Medical Devices
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1PermeaDerm Product Sales
TypeHardware Sales
Description

Revenue generated from sale of FDA-cleared PermeaDerm medical device products (PermeaDerm-B, -C, and -G) for burns, diabetic ulcers and chronic wounds. Products commercialized in U.S., Europe and Greater China markets through distribution partnerships.

stedical.com
2Clinical Trial Services
TypeProfessional Services
Description

Multi-center clinical studies conducted in China (184 subjects across 4 centers) and United States for regulatory approval expansion and clinical evidence generation.

stedical.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1PermeaDerm® Biosynthetic Wound Matrix
Description

Biosynthetic matrix technology for wound management of chronic wounds and burns, including PermeaDerm B (acute wounds), PermeaDerm C (chronic wounds), and PermeaDerm G (hand burn gloves)

stedical.com
+3 more records
Core offering1 text field

PermeaDerm develops and manufactures FDA-cleared 510(k) biosynthetic wound matrix products for the treatment of burns, diabetic ulcers, and chronic wounds. The product family includes PermeaDerm-B for acute wounds, PermeaDerm-C for chronic wounds, and PermeaDerm-G gloves for hand burns, all based on a proprietary Biosynthetic Matrix (BSM) technology featuring variable porosity and a 3D micro-scaffold structure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Deep second-degree burns healed in 9 days with single application, compared to typical 3-7 week healing time
+3 more records
Product overview1 text field

PermeaDerm is a family of FDA-cleared 510(k) biosynthetic wound matrix products developed by Stedical Scientific following its 2019 acquisition of PermeaDerm, Inc. The portfolio consists of PermeaDerm-B for acute wounds, PermeaDerm-C for chronic wounds, and PermeaDerm-G for hand burn treatment. All products are based on a proprietary Biosynthetic Matrix (BSM) Technology featuring a silicone membrane epidermal analogue and 3D micro-scaffold dermal analogue that creates an optimal moist wound healing environment through the R.A.S.E. (Reconstruction, Adherence, Secondary adherence, Epithelialization) mode of action.

Product and service4 records
1PermeaDerm® Biosynthetic Wound Matrix
CategoryBiosynthetic Wound Matrix
Description

FDA-cleared 510(k) biosynthetic wound matrix medical device combining an epidermal analogue (silicone membrane with variable slits) and dermal analogue (3D micro-scaffold with bio-coating) to create a moist healing environment. Uses R.A.S.E. mode of action: Reconstruction of skin barrier and ECM, Primary Adherence, Secondary Adherence, and Epithelialization. For healthcare providers treating burn and chronic wound patients.

2PermeaDerm-B
CategoryAcute Wound Care
Description

FDA-cleared 510(k) medical device variant for acute wounds including partial thickness burns, donor sites, coverage of meshed autograft, surgical wounds, abrasions, lacerations, and skin tears.

3PermeaDerm-C
CategoryChronic Wound Care
Description

FDA-cleared 510(k) medical device variant for chronic wounds including pressure sores, venous ulcers, diabetic ulcers, and vascular ulcers.

4PermeaDerm-G (Gloves)
CategorySpecialty Burn Care
Description

FDA-cleared 510(k) medical device specifically designed as gloves for treatment of debrided partial thickness hand burns and other partial thickness hand wounds.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-05
Description

Stedical announced Burn Clinical Trial enrollment at the ABA Townhall meeting during the 54th American Burn Association annual meeting in Las Vegas, April 5-8, 2022.

2Shanghai Changhai Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-12
Description

Key clinical research partner for PermeaDerm clinical trials in China. Led by China National Engineering Academician Dr. Zhaofan Xia. Stedical initiated first discussion with this hospital in 2019 regarding clinical development of PermeaDerm technology in China.

stedical.com
3Wuxi Affiliated Hospital of Jiangnan University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-12
Description

Clinical trial partner led by Dr. Guozhong Lv, Chairman of China Burn Association. Participated in Clinical Trial Investigator Symposium and contributes to study design.

stedical.com
4Shanghai Ruijin Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-12
Description

Clinical trial partner led by Dr. Yan Liu, Vice Chairman of China Burn Association. Participated in multi-center clinical study design and implementation.

stedical.com
5Tongren Hospital (Wuhan University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-12
Description

Clinical trial partner led by Dr. Weiguo Xie, Director of Burn Department and past Vice President of China Burn Association. Contributed to clinical trial design.

stedical.com
6Dr. David Herndon
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-12
Description

Member of US National Academy of Medicine, Editor of Journal of Burn Care and Research, and Chairman of Scientific Advisory Committee at Stedical Scientific in both China and the U.S. Joined via video conference to symposium, providing historical context and endorsement of PermeaDerm technology.

stedical.com
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2019-08-08
Description

Jones Day acted as legal counsel to Stedical Scientific in the United States for the acquisition of PermeaDerm, Inc.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2019-08-08
Description

King & Wood Mallesons acted as legal counsel to Stedical Scientific in China for the acquisition transaction.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Organogenesis markets Apligraf and Dermagraft, leading living-cell skin substitutes for chronic wounds and burns. It competes head-to-head with PermeaDerm in advanced wound care across diabetic foot ulcers, venous ulcers, and burn coverage.

TypeEmerging player
Description

Avita Medical sells the RECELL system, an autologous cell-harvesting platform for burns and wound treatment. It targets the same burn-center customers as PermeaDerm with a differentiated point-of-care cell therapy approach.

TypeBroad incumbent
Description

Coloplast provides wound-care and skin-care dressings (Biatain, etc.) used for chronic wounds and burns. It is a broad incumbent in advanced wound care with established distribution channels overlapping PermeaDerm's targets.

TypeBroad incumbent
Description

Smith+Nephew is a global wound-care leader whose Advanced Wound Management portfolio (including ALLEVYN, DURAFIBER, and historically Biobrane) overlaps with PermeaDerm's burn and chronic-wound use cases. As the original commercializer of Biobrane, it is the benchmark PermeaDerm explicitly aims to surpass.

TypeDirect peer
Description

MiMedx sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) used as skin substitutes for chronic wounds and surgical applications. It is a directly competing skin-substitute platform targeting the same burn and chronic-wound call points.

TypeEmerging player
Description

Aroa Biosurgery develops ovine forestomach-derived extracellular matrix wound products (Endoform, Myriad) for chronic and surgical wounds. It is an emerging skin-substitute and regenerative wound-care peer with similar hospital-segment targeting.

TypeDirect peer
Description

Integra LifeSciences manufactures Integra Dermal Regeneration Template and other skin-substitute / regenerative wound-care products. It is the most direct competitor to PermeaDerm in the biosynthetic and biologic skin-substitute category for burns and chronic wounds.

TypeBroad incumbent
Description

Mölnlycke provides Mepilex, Mepitel, and other advanced wound dressings used across burns and chronic wounds globally. It competes with PermeaDerm as a broad incumbent with established hospital contracts and international distribution.

TypeBroad incumbent
Description

ConvaTec offers AQUACEL and other advanced wound-care products for chronic wounds and burns. Its portfolio overlaps PermeaDerm's chronic-wound segment (diabetic, venous, pressure ulcers) and competes in the same hospital formularies.

TypeEmerging player
Description

Vericel markets Epicel (cultured epidermal autografts) for severe burns. It competes with PermeaDerm-G in deep and hand-burn treatment, particularly in US burn centers where adoption decisions are made.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PermeaDerm

Biosynthetic Wound Care Medical Devicespermeaderm.com

PermeaDerm develops FDA-cleared biosynthetic wound matrix products (PermeaDerm-B, -C, -G) for burn, chronic, and surgical wound care, leveraging variable porosity and R.A.S.E. healing technology, commercialized via distribution partners in the US, Europe, and Greater China.

What PermeaDerm does

PermeaDerm, Inc. is a San Diego-based medical device company that develops and commercializes a family of FDA 510(k)-cleared biosynthetic wound matrix products for the treatment of burns, chronic wounds, and surgical or traumatic wounds. The company's proprietary Biosynthetic Matrix (BSM) Technology combines a silicone membrane epidermal analogue (with variable slits for oxygen, carbon dioxide, and exudate diffusion) and a 3D micro-scaffold dermal analogue with bio-coating, configured with variable porosity to allow customization across wound types. The portfolio consists of three product variants: PermeaDerm-B for acute wounds (partial thickness burns, donor sites, surgical wounds), PermeaDerm-C for chronic wounds (diabetic ulcers, venous ulcers, pressure sores, vascular ulcers), and PermeaDerm-G (gloves) for debrided partial thickness hand burns. The technology operates through an R.A.S.E. mode of action — Reconstruction of skin barrier and ECM, primary Adherence within 5 hours, secondary Adherence (3D structure) within 72 hours, and Epithelialization.

PermeaDerm was founded by Dr. Aubrey Woodroof, the inventor of Biobrane (the first bilaminate biosynthetic temporary wound dressing) and holder of multiple patents covering Biobrane, AWOD, AWOD Plus, and PermeaDerm. The company received FDA 510(k) clearance in 2016 and ISO 13485 certification in 2018. In August 2019, PermeaDerm was acquired by Stedical Scientific (Shanghai) Co., Ltd., with Dr. Woodroof continuing as Chief Scientific Officer. Following the acquisition, Stedical Scientific provides the R&D and manufacturing infrastructure while leveraging top-tier distribution partners in the wound care, infection control, and burn markets for commercialization across the US, Europe, and Greater China. The company is also running multi-center clinical trials in the US and China (184 subjects across 4 Chinese centers) to support expanded regulatory approval and clinical evidence, with stated expansion intent into the Middle East, Southeast Asia, Africa, and Latin America.

The business model is primarily hardware sales of FDA-cleared medical devices through distribution partners, supplemented by clinical trial services in support of regulatory expansion. Pricing is not publicly disclosed. The company reports that thousands of patients have been treated in US burn centers since the 2020 US launch, with a cited clinical outcome of 9-day healing for deep second-degree burns versus a typical 3-7 week healing time. No revenue figures, headcount, or funding rounds are publicly disclosed.

PermeaDerm firmographics

Firmographics
Name
PermeaDerm
Legal name
PermeaDerm, Inc.
Website
https://permeaderm.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
1–10 employees
Short description
PermeaDerm develops FDA-cleared biosynthetic wound matrix products (PermeaDerm-B, -C, -G) for burn, chronic, and surgical wound care, leveraging variable porosity and R.A.S.E. healing technology, commercialized via distribution partners in the US, Europe, and Greater China.
Ownership category
akta.pro rank

PermeaDerm industry classification

Industry
Product category
Biosynthetic Wound Care Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAKACAN
Wound Care & Ulcer Management
SECONDARYHLAKAGAK
Wound Care & Diabetic Foot Infection
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAFAHAF
Burn Care Specialty Hospitals
Healthcare & Life Sciences/Healthcare Providers & Systems/Specialty Hospitals & Inpatient Specialty Care

Keywords

  • Biosynthetic wound matrix
  • Burn care dressings
  • Chronic wound care
  • Skin substitute devices
  • Medical device manufacturing

Where PermeaDerm is headquartered

Location

Headquarters

HQ city
Carlsbad
HQ country
United States
HQ region
North America

Offices2 records

Markets served

PermeaDerm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. PermeaDerm Product Sales: Revenue generated from sale of FDA-cleared PermeaDerm medical device products (PermeaDerm-B, -C, and -G) for burns, diabetic ulcers and chronic wounds. Products commercialized in U.S., Europe and Greater China markets through distribution partnerships.
  2. Clinical Trial Services: Multi-center clinical studies conducted in China (184 subjects across 4 centers) and United States for regulatory approval expansion and clinical evidence generation.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

PermeaDerm product offering

Product offering

Core offering

PermeaDerm develops and manufactures FDA-cleared 510(k) biosynthetic wound matrix products for the treatment of burns, diabetic ulcers, and chronic wounds. The product family includes PermeaDerm-B for acute wounds, PermeaDerm-C for chronic wounds, and PermeaDerm-G gloves for hand burns, all based on a proprietary Biosynthetic Matrix (BSM) technology featuring variable porosity and a 3D micro-scaffold structure.

Product overview

PermeaDerm is a family of FDA-cleared 510(k) biosynthetic wound matrix products developed by Stedical Scientific following its 2019 acquisition of PermeaDerm, Inc. The portfolio consists of PermeaDerm-B for acute wounds, PermeaDerm-C for chronic wounds, and PermeaDerm-G for hand burn treatment. All products are based on a proprietary Biosynthetic Matrix (BSM) Technology featuring a silicone membrane epidermal analogue and 3D micro-scaffold dermal analogue that creates an optimal moist wound healing environment through the R.A.S.E. (Reconstruction, Adherence, Secondary adherence, Epithelialization) mode of action.

Differentiator

Problem solved

Functional benefit

Brands

  • PermeaDerm® Biosynthetic Wound Matrix: Biosynthetic matrix technology for wound management of chronic wounds and burns, including PermeaDerm B (acute wounds), PermeaDerm C (chronic wounds), and PermeaDerm G (hand burn gloves)
  • PermeaDerm Gloves
  • PermeaDerm-B
  • PermeaDerm-C

Products and services

  • PermeaDerm® Biosynthetic Wound Matrix FDA-cleared 510(k) biosynthetic wound matrix medical device combining an epidermal analogue (silicone membrane with variable slits) and dermal analogue (3D micro-scaffold with bio-coating) to create a moist healing environment. Uses R.A.S.E. mode of action: Reconstruction of skin barrier and ECM, Primary Adherence, Secondary Adherence, and Epithelialization. For healthcare providers treating burn and chronic wound patients.
  • PermeaDerm-B FDA-cleared 510(k) medical device variant for acute wounds including partial thickness burns, donor sites, coverage of meshed autograft, surgical wounds, abrasions, lacerations, and skin tears.
  • PermeaDerm-C FDA-cleared 510(k) medical device variant for chronic wounds including pressure sores, venous ulcers, diabetic ulcers, and vascular ulcers.
  • PermeaDerm-G (Gloves) FDA-cleared 510(k) medical device specifically designed as gloves for treatment of debrided partial thickness hand burns and other partial thickness hand wounds.

Quantifiable outcome

  • Deep second-degree burns healed in 9 days with single application, compared to typical 3-7 week healing time
  • +3 more outcomes

Companies that use PermeaDerm

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

PermeaDerm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

PermeaDerm partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • American Burn AssociationcoreStrategic or Co-development Partner · 5 April 2022Stedical announced Burn Clinical Trial enrollment at the ABA Townhall meeting during the 54th American Burn Association annual meeting in Las Vegas, April 5-8, 2022.
  • Shanghai Changhai HospitalcoreStrategic or Co-development Partner · 12 January 2021Key clinical research partner for PermeaDerm clinical trials in China. Led by China National Engineering Academician Dr. Zhaofan Xia. Stedical initiated first discussion with this hospital in 2019 regarding clinical development of PermeaDerm technology in China.
  • Wuxi Affiliated Hospital of Jiangnan UniversitycoreStrategic or Co-development Partner · 12 January 2021Clinical trial partner led by Dr. Guozhong Lv, Chairman of China Burn Association. Participated in Clinical Trial Investigator Symposium and contributes to study design.
  • Shanghai Ruijin HospitalcoreStrategic or Co-development Partner · 12 January 2021Clinical trial partner led by Dr. Yan Liu, Vice Chairman of China Burn Association. Participated in multi-center clinical study design and implementation.
  • Tongren Hospital (Wuhan University)coreStrategic or Co-development Partner · 12 January 2021Clinical trial partner led by Dr. Weiguo Xie, Director of Burn Department and past Vice President of China Burn Association. Contributed to clinical trial design.
  • Dr. David HerndoncoreStrategic or Co-development Partner · 12 January 2021Member of US National Academy of Medicine, Editor of Journal of Burn Care and Research, and Chairman of Scientific Advisory Committee at Stedical Scientific in both China and the U.S. Joined via video conference to symposium, providing historical context and endorsement of PermeaDerm technology.
  • Jones DayminorImplementation/ SI/ Consulting Partner · 8 August 2019Jones Day acted as legal counsel to Stedical Scientific in the United States for the acquisition of PermeaDerm, Inc.
  • King & Wood MallesonsminorImplementation/ SI/ Consulting Partner · 8 August 2019King & Wood Mallesons acted as legal counsel to Stedical Scientific in China for the acquisition transaction.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

PermeaDerm competitors and assessment

Company assessment

Direct peers

  • Organogenesis: Organogenesis markets Apligraf and Dermagraft, leading living-cell skin substitutes for chronic wounds and burns. It competes head-to-head with PermeaDerm in advanced wound care across diabetic foot ulcers, venous ulcers, and burn coverage.
  • MiMedx: MiMedx sells dehydrated amniotic membrane allografts (EpiFix, AmnioFix) used as skin substitutes for chronic wounds and surgical applications. It is a directly competing skin-substitute platform targeting the same burn and chronic-wound call points.
  • Integra LifeSciences: Integra LifeSciences manufactures Integra Dermal Regeneration Template and other skin-substitute / regenerative wound-care products. It is the most direct competitor to PermeaDerm in the biosynthetic and biologic skin-substitute category for burns and chronic wounds.

Emerging players

  • Avita Medical: Avita Medical sells the RECELL system, an autologous cell-harvesting platform for burns and wound treatment. It targets the same burn-center customers as PermeaDerm with a differentiated point-of-care cell therapy approach.
  • Aroa Biosurgery: Aroa Biosurgery develops ovine forestomach-derived extracellular matrix wound products (Endoform, Myriad) for chronic and surgical wounds. It is an emerging skin-substitute and regenerative wound-care peer with similar hospital-segment targeting.
  • Vericel: Vericel markets Epicel (cultured epidermal autografts) for severe burns. It competes with PermeaDerm-G in deep and hand-burn treatment, particularly in US burn centers where adoption decisions are made.

Broad incumbents

  • Coloplast: Coloplast provides wound-care and skin-care dressings (Biatain, etc.) used for chronic wounds and burns. It is a broad incumbent in advanced wound care with established distribution channels overlapping PermeaDerm's targets.
  • Smith+Nephew: Smith+Nephew is a global wound-care leader whose Advanced Wound Management portfolio (including ALLEVYN, DURAFIBER, and historically Biobrane) overlaps with PermeaDerm's burn and chronic-wound use cases. As the original commercializer of Biobrane, it is the benchmark PermeaDerm explicitly aims to surpass.
  • Mölnlycke Health Care: Mölnlycke provides Mepilex, Mepitel, and other advanced wound dressings used across burns and chronic wounds globally. It competes with PermeaDerm as a broad incumbent with established hospital contracts and international distribution.
  • ConvaTec: ConvaTec offers AQUACEL and other advanced wound-care products for chronic wounds and burns. Its portfolio overlaps PermeaDerm's chronic-wound segment (diabetic, venous, pressure ulcers) and competes in the same hospital formularies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PermeaDerm social profiles

Digital presence

PermeaDerm compliance and trust

Trust signal

Compliance2 records

PermeaDerm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PermeaDerm leadership team

Management profile

Number of profiles

Profiles3 records

PermeaDerm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PermeaDerm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PermeaDerm

What does PermeaDerm do?

PermeaDerm develops and manufactures FDA-cleared 510(k) biosynthetic wound matrix products for the treatment of burns, diabetic ulcers, and chronic wounds. The product family includes PermeaDerm-B for acute wounds, PermeaDerm-C for chronic wounds, and PermeaDerm-G gloves for hand burns, all based on a proprietary Biosynthetic Matrix (BSM) technology featuring variable porosity and a 3D micro-scaffold structure.

Is PermeaDerm a public or private company?

PermeaDerm is a private company. It is classified as corporate owned and is currently acquired.

When was PermeaDerm founded?

PermeaDerm was founded in 2013. It employs 1 to 10 people.

Where is PermeaDerm based?

PermeaDerm is headquartered in Carlsbad, United States, in the North America region.

How does PermeaDerm make money?

Two revenue lines are on record. PermeaDerm Product Sales are the primary driver. The others are clinical Trial Services.

Who are PermeaDerm's main competitors?

Direct peers on record are Organogenesis, MiMedx and Integra LifeSciences. Emerging players are Avita Medical, Aroa Biosurgery and Vericel. Broad incumbents are Coloplast, Smith+Nephew, Mölnlycke Health Care and ConvaTec.

Does PermeaDerm have an API?

No public API is recorded for PermeaDerm.

What industry is PermeaDerm in?

PermeaDerm's product category is Biosynthetic Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals